ESMO-GI 2022


Tucatinib | Gastric or GEJ Adenocarcinoma | P-156

MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in Progress

Tucatinib | Solid Tumors | P-74

SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: biliary tract cancer cohort (Trial in Progress)

Tucatinib | Colorectal Cancer | LBA-2

MOUNTAINEER: Open-label, phase 2 study of tucatinib in combination with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017)